Whereas this is not the first report on generation of suppressive DCs, it delineates a method using a clinically approved drug at nontoxic concentrations, which yields irreversibly changed DCs, effective across species in vitro and in vivo.
T he role of autoantigens and autoreactive lymphocytes in the initiation and maintenance of autoimmune diseases has been controversially discussed (1) . Even if self-antigens were not the primordial cause of some autoimmune conditions, they offer a way of directing an immunosuppressive effect to the diseased organ, and therefore constitute a promising alternative to the commonly used, broadly reactive immunosuppressants. The ''holy grail'' for autoimmunity is not the disease-causing antigen, but the disease-curing antigen (2) . In a clinical trial, an immunomodulatory peptide derived from hsp60-one of the known target self-antigens-was injected into patients with newly diagnosed type 1 diabetes. Although the study was small, it suggested that the peptide treatment preserved endogenous insulin production (3) . Tolerance induction was also attempted by oral administration of self-antigens. This has been tried with myelin in multiple sclerosis (MS), collagen in rheumatoid arthritis, and insulin in type I diabetes. Despite success with the prevention of diseases in animal models, clinical trials attempting to treat an ongoing disease in humans have thus far been unsuccessful (4) . What has been learned from animal models and a few clinical studies is that autoantigens must be presented in a nonimmunogenic form, usually by altering their structure. A successful example for the latter strategy is treatment of MS patients with copaxone, a synthetic peptide that mimics the composition of the central nervous component, myelin basic protein (MBP) (4) .
Dendritic cells (DCs) are commonly thought of as strongly stimulatory cells, but DCs can also suppress the immune response (5) . Evidently, evolution has developed highly efficient mechanisms for protecting tissues and organs from self-destruction, one of them being mediated by DCs (5) . What nature applies for protection from self-attack might be used by man for treatment of autoimmune diseases or graft rejection. Unfortunately, natural suppressive DCs are hard to define phenotypically, and therefore difficult to use for therapeutic applications. For example, it has been shown that immature DCs induce tolerance, whereas mature DCs activate immune responses (5) . However, a growing body of recent evidence indicates that DC maturation per se is not a distinguishing feature of immunogenicity, as opposed to tolerogenicity (6) . It is presently believed that the development of an immunogenic or tolerogenic response depends on the net effect of antigen dose, DC lineage and maturational status, DC stimulation by pathogen-derived products, and the cytokine milieu (5, 6) . Given the hardly predictable suppressive function of natural DCs, a reasonable alternative for therapeutic purposes would be the in vitro generation of inhibitory DCs. Several methods have been described for designing suppressive DCs (7) . A major risk of deliberately generated inhibitory DCs is their potential reversibility to a stimulatory status. Furthermore, their effectiveness may be limited to certain species. In previous studies we showed that treatment of DCs with mitomycin C (MMC) stably transforms stimulatory into inhibitory cells (8) . A single injection of such donor DCs into the recipient before heart transplantation suppressed heart allograft rejection in rats (8) .
The strategy for controlling autoimmune reactions envisaged herein is to load MMC-treated human or murine DCs with selfantigens and to use these ''inhibitory bullets'' for targeted suppression of specific self-reactive T cells in vitro and in vivo.
MBP-Loaded MMC-DCs Inhibit Specific T Cells of MS Patients in Vitro.
DCs derived from MS patients were loaded with MBP and coincubated with autologous T cells. In a parallel experiment, the DCs were loaded with MBP and treated with MMC. Whereas untreated DCs induced strong T cell stimulation, MMC-DCs did not (Fig. 1A) .
Therapy of patients with active MS should address already activated autoreactive T cells. To find out whether these lymphocytes can be controlled by inhibitory DCs, preactivated MBPspecific T cells derived from an MS patient were incubated with HLA-DR-matched, MBP-loaded MMC-DCs. The response of these T cells was significantly reduced (Fig. 1B) . By contrast, MBP-loaded/MMC-untreated DCs strongly stimulated the T cells, whereas naïve DCs or DCs loaded with an irrelevant peptide did not result in stimulation (data not shown).
In the next experiment, we investigated whether suppressed T cells can be restimulated with naïve MBP-loaded DCs of the same donor. The results showed that, once suppressed by MMC-DCs, T cells cannot or can only weakly be reactivated ( Fig. 1 C and D) .
It is important to note that the suppressive capacity of DCs depends on MMC concentrations during pretreatment. Optimal T cell suppression is obtained at high doses.
Supernatants of Mitomycin-Treated DCs Do Not Inhibit the T Cells.
Upon treatment of DCs with MMC, a certain amount of substance might have diffused from the intracellular compartment into the culture medium and blocked T cell proliferation. To exclude that, supernatants of MMC-treated DCs were collected and used as medium in T cell proliferation assays. The results showed that T cell proliferation was not significantly affected [supporting information (SI) Fig. S1 ], indicating that leakage of MMC from treated cells is not the reason for suppression.
T Cells Are Blocked in the G0/G1 Phase. When analyzing the mechanism of suppression, two aspects must be considered: the reaction of T cells to inhibitory DCs and the molecular changes of DCs induced by MMC-treatment.
As shown in the previous experiment, restimulation of suppressed T cells was not or only partially possible, indicating that the cells either became areactive or died. Cell cycle analysis revealed a significant accumulation in the G 0 /G 1 phase of T cells coincubated with MMC-DCs (Fig. S2 ). This finding argues for induction of T cell areactivity. A comprehensive gene scan of 47,000 transcripts and additional variants was carried out by affymetrix microarray analysis. Genes whose expression was changed significantly upon treatment of DCs with MMC in three independent experiments were further analyzed. Based on this criterion, 116 genes were identified (Table S1 ). Among the affected genes, two main clusters were found: one involved in apoptosis and the other mediating immunosuppression. Functionally relevant genes are highlighted in Table S1 (column 3) and their full names as well as the proteins they are coding for are shown in column 4. Quantitative RT-PCR (data not shown) of the most important candidates confirmed the affymetrix microarray data. Among apoptosisrelated genes, six proapoptotic genes were up-regulated (LRDD, TNFRSF 10b, PERP, FDXR, TRAF4, DDIT3) and five antiapoptotic genes down-regulated (NRG2, CFLAR, I-FLICE, Usurpin, FLAME-1), pointing to induction of cell death by apoptosis. It has been speculated that apoptotic cells are tolerogenic (12, 13) . Therefore, it was important to verify by FACS whether the changed expression of these genes had repercussions on cell viability. As shown in Fig. 2 , MMC-treated DCs enter earlier into apoptosis than untreated DCs. Interestingly, in parallel to apoptotic genes, well known immunosuppressive genes (ADM, TSC22D3, LILRB4) (14-16) were up-regulated along with a series of potentially inhibitory genes (MAFB, CSF2RA, MAP4K4, GAB2) (17) (18) (19) (20) (21) . Taken together, these findings indicate induction of apoptosis and increased expression of immunosuppressive genes in DCs treated with MMC.
MBP-Loaded MMC-DCs Inhibit Specific Mouse T Cells in Vitro.
We addressed the question of whether the suppressive effect mediated by MMC-DCs in vitro also works in vivo. For clarifying this point, a mouse EAE model was chosen, a setting in which MBP-specific T cells cause an inflammatory disease, similar to the inflammation of MS in humans. A prerequisite for their effectiveness in vivo was that, similar to human DCs, MMC-treated mouse DCs were T cell suppressive in vitro. Cell culture studies showed that mouse DCs loaded with MBP and treated with MMC significantly suppress specific syngeneic T cells of Tg4 mice (MBP-MMC-DCs ϩ T cells ϭ 12,653 Ϯ 923 versus MBP-DCs ϩ T cells ϭ 24,727 Ϯ 3197; naïve DCs ϩ T cells ϭ 7,007 Ϯ 1,591) (mean of cpm Ϯ SEM) (P ϭ 0.022).
Previous observations of Liu et al. (13) showed that, when injected into mice, antigen-loaded tolerogenic cells first drive antigen-specific T cells into cell-cycle, and subsequently the T cells are inactivated. This finding prompted us to trace the fate of the deleterious autoreactive T cells in animals treated with inhibitory DCs. MBP-specific T cells were labeled ex vivo with CFSE and injected into syngeneic mice. Thereafter, the animals were injected intravenously with MBP-loaded DCs treated with MMC, and T cells were isolated and analyzed by FACS. The MBP-specific T cells showed a significant degree of proliferation (MBP-MMC-DC ϭ 25% versus MBP-DC ϭ 22%). Evidently, despite initial stimulation, the T cells must have been subsequently inactivated because, as shown in the following in vivo experiment, they were not able to cause EAE. This finding is in line with the observation described by Liu et al. (13) .
Vaccination with MBP-Loaded MMC-DCs Protects Mice from EAE.
MBP-loaded untreated DCs were injected into animals and, as expected, severe EAE occurred within 2 to 3 weeks (Fig. 3A) . If MBP-loaded DCs were pretreated with MMC and then injected, however, the animals remained completely free of symptoms, showing that MBP-specific T cells were not activated. An interesting question was whether the symptom-free animals became resistant to EAE. To this end, treated animals were rechallenged with MBP-DCs. To our disappointment, they developed a significant degree of EAE (Fig. 3B) . One must keep in mind that the transgenic Tg4 mice used in our study carry Ͼ90% MBP-specific T cells, in contrast to only Ͻ0.0001% in normal rodents (9, 22) . We suspected that it might be difficult to inactivate such a large number of T cells with one injection only. Therefore, in a subsequent experiment the animals were treated five times with MBP-MMC-DCs and then rechallenged (Fig. 4A ). As shown in Fig. 4B , this time the result was positive: whereas controls, which had not been vaccinated with MBP-MMC-DCs developed severe EAE with lethal outcome, prevaccinated mice recovered after a mild episode of disease. Evidently, prophylactic vaccination with autoantigen-loaded DCs is possible.
Discussion
Attempts to generate regulatory DCs for control of autoimmune reactions have recently been described. Enk and colleagues generated suppressive DCs by incubating the cells in vitro with IL-10 and inhibited ovalbumin-specific CD4 T cell responses in naïve and sensitized mice (23). Huang et al. (24) observed that a subpopulation of immature bone marrow-derived DCs, if pulsed with MBP and injected into syngeneic rats, are protected from clinical EAE. Others showed that, to the contrary, mature but not immature DCs injected into mice with EAE reduced the severity of clinical signs and inflammation in the CNS (25) . These conflicting findings stress the functional plasticity, from immunostimulation to suppression, of DCs under various conditions. Clinical signs of disease could also be reduced if rats or mice with incipient EAE were injected with IFN-␥-treated DCs (26) . In neither of the latter two studies were antigen-specific DCs used. By contrast, Menges et al. (27) used TNF-␣ matured DCs pulsed with autoantigenic peptide and observed protection from EAE if the mice were injected before inductive immunization. Another experimental study suggested that inhibition of NF-kB by pharmacological agents enhanced the capacity of immature DCs to induce antigen-specific suppression to self-antigens in mice (28) . When murine DCs were transduced with the gene for suppressor of cytokine signaling-3, they exhibited a DC2 phenotype that promoted Th2 cell differentiation and weakly influenced autoimmune reactions in vivo (29) . The severity of EAE in mice could also be reduced with autoantigen-loaded DCs expressing TRAIL or PDL1 transgenes (30) .
Different functional behaviors of DCs belonging to the same maturational stage (5, 6) 
Based on our previous experience in rats (8) , in which allograft rejection was successfully controlled by MMC-DCs, stably inhibitory DCs for control of autoimmunity were generated in the present study by treating the cells with MMC and loading with autoantigen. These cells protected animals from lethal EAE, showing that, in principle, effective prophylactic vaccination against T cell-mediated autoaggression is possible. A further question was whether MBP-MMC-DCs can inhibit induction of EAE if coadministered with the stimulatory MBP-DCs. Our findings showed that suppressive DCs have the capacity to inhibit the stimulatory action of MBP-DCs and limit the extent of subsequent EAE (data not shown). MMC is an alkylating agent used in cancer therapy that strongly binds to distinct DNA sites, cross-links the double helical strands, inhibits DNA synthesis, and consequently suppresses cell proliferation. In addition, MMC inhibits RNA and protein synthesis. Interestingly, alkylating agents not only inhibit but also activate pathways usually triggered by stimulatory agents (31) . Therefore, it is not surprising that in our model the expression of certain DC-genes was up-and not down-regulated. Because of the irreversible interaction of MMC with intracellular compounds, cells do not release MMC upon incubation with this substance. This was confirmed by our finding that supernatants of MMC-treated DCs do not significantly suppress T cell reactions. Most importantly, in contrast to manipulations of DCs with biological agents (e.g., cytokines), MMCtreatment induces irreversibly suppressive DCs by induction of apoptosis, a feature that offers a potential for developing a stable therapeutic tool. Another advantage of this model is the use of nontoxic doses of a clinically approved drug. The therapeutic dose of MMC is 10 to 20 mg/m 2 ; the concentration of MMC used in this study for incubation of cells was 0.05 to 0.100 mg/ml. Our analyses showed that after extensive washing the cell suspension contained, if at all, nonactive traces of MMC. No clinical side effects are expected at these minimal amounts of free MMC in the injected solution.
Our findings demonstrate that MMC-DCs are effective in controlling both mouse and human autoreactive T cells. Previous studies in our laboratory showed that MMC-DCs are strongly inhibitory in rats (8) . In contrast with other models, the therapeutic tool described herein works across species. Moreover, in the present study the in vivo effect was tested under aggravating conditions. Normal rodents carry Ͻ10 Ϫ6 MBP-reactive T cells in their repertoire (22) . We used Tg4 transgenic mice with Ͼ90% MBP-reactive T cells and consequently with an extreme proneness to EAE (9) . If this huge number of ''dangerous'' T cells can be kept in check, we can expect a reliable effect when lower numbers of autoreactive T cells are involved.
In former times, MMC was used in DC-induced T-cell activation experiments to suppress proliferation of contaminating cells in the DC preparation. Later on, MMC was replaced with ionizing irradiation of cells. Here, the question must be addressed why in those experiments MMC-treated DCs stimulated and in our experiments they suppressed T-cell proliferation. We also had certain degree of stimulation in our cultures. The extent of T-cell proliferation was dose dependent, i.e. the less MMC was used for treatment of DCs, the higher the stimulation. Apparently, in former experiments, this stimulation was sufficient to study T-cell responses. In the current series of experiments, we did the next step and analyzed restimulation of T cells cocultured with MMC-DCs. In contrast to T cells activated with untreated DCs, those cocultured with MMC-DCs showed significantly suppressed proliferation. This finding was further supported by our observation that CFSE-labelled T cells injected into mice treated with MMC-DCs proliferated first, but subsequently the animals became resistant to EAE. Apparently, MMC-DC treatment induces initial activation but thereafter MBP-specific T cells are inactivated. A similar finding was reported by Liu et al. regarding the induction of tolerance in mice by antigen-loaded tolerogenic cells (13) . Other factors that possibly influence the extent of T-cell suppression in vitro and which might have varied among studies are the percentage of apoptotic cells in the MMC-DC preparation, the DC:T-cell ratio, and the maturational stage of DCs.
A previous study showed that exposure to necrotic tumor cells, in contrast to exposure to apoptotic cells, induces immunostimulation (12) . This observation, as well as other observations (13), led to the hypothesis that necrotic cell death is immunogenic, whereas apoptotic cell death is poorly immunogenic or even tolerogenic. From a physiological view this makes sense, because apoptosis is the normal process of cell death in our tissues. Would apoptosis induce immune responses, it would lead to inflammation and autoimmunity. Liu et al. (13) used this phenomenon to actively induce tolerance. Dying apoptotic splenocytes were loaded with ovalbumin and injected into syngeneic mice. After an initial phase of T cell stimulation, the recipients became tolerant to ovalbumin (13) . It is interesting to note the reports showing that DC lifespan has important consequences for DC-T cell interaction, and thus determines the immunological outcome. Hugues et al. concluded that stable interactions favor T cell priming, whereas brief contacts between DCs and T cells may contribute to the induction of T cell tolerance (32) . In the present series of experiments, MMC accelerated the natural process of apoptosis, shortening the lifespan of injected DCs and thus their contact with T cells. This provides a possible explanation for the observed tolerogenic effect. Obeid et al. (33) have recently analyzed the immunogenic potential of tumor cells rendered apoptotic by various chemotherapeutic drugs and observed that anthracyclins generate stimulatory cells, whereas other drugs, such as mitomycin C, do not. If anthracyclins were used, the chaperon protein calreticulin was up-regulated and responsible for the stimulatory action. This finding is important for tumor therapy, which aims at killing malignant cells and concomitantly stimulating the immune response against the tumor. Our findings are interesting in this context by demonstrating that treatment with MMC renders the cells apoptotic but-as shown by affymetrix microarray-does not up-regulate calreticulin; instead, it up-regulates immunosuppressive molecules. Whereas the observation of Obeid et al. (33) may be used for improving chemotherapy in cancer, our observation has a therapeutic potential for controlling autoimmune disease or graft rejection.
In the present study, induction of apoptosis was suggested by up-regulation of proapoptotic genes, including LRDD (coding for PIDD), TNFRSF10b (coding for TRAIL-R2), PERP, FDXR, TRAF4, and DDIT3. Additionally, we noted down-regulation of genes that protect from apoptosis, such as NRG2 and CFLAR (coding for cFLIP and its variants I-FLICE, usurpin, FLAME-1). Most importantly, apoptosis of MMC-treated DCs was demonstrated by FACS.
Gene expression analysis showed that, concomitantly with induction of apoptosis, a series of strongly immunosuppressive genes were up-regulated. ADM (adrenomedullin), whose expression was increased 10 times, is a peptide that prevents sepsis-induced mortality, abrogates colitis, and provides highly effective therapy of arthritis by decreasing the presence of autoreactive Th1 cells, inducing regulatory T cells and inhibiting autoimmune and inflammatory responses (14) . ADM also up-regulates TGF-␤. Gene expression analysis showed unchanged TGF-␤ expression. However, this reflects the status 18 h following MMC-treatment, the point in time when gene scan was performed. It is conceivable that increased TGF-␤ expression occurs at a later point. TGF-␤-mediated suppression might also play a role in another context. Fadok et al. (34) showed that phagocytosis of apoptotic cells by human macrophages increases their TGF-␤ expression. Transferred to our model, that means that administration of apoptotic DCs in vivo might increase TGF-␤ production and contribute to the described suppression of autoreactive T cells. On the other hand, Chen et al. (35) showed that apoptotic cells per se release TGF-␤, thereby contributing to the generation of an immunosuppressive milieu. In their studies, TGF-␤ release was not associated with up-regulation of TGF-␤ transcription, suggesting release of existing intracellular stocks rather than de novo synthesis. Translated to our system, this indicates that MMC-DCs release their intracellular TGF-␤ without up-regulating its expression. Another gene whose expression was up-regulated by MMC was TSC22D3 (coding for GILZ). Interestingly, the same gene is up-regulated upon exposure of DCs to glucocorticoids, IL-10, or TGF-␤, all well known immunological inhibitors (15) . GILZ confers a suppressive phenotype to DCs and prevents them from activating T cells (15) . A molecule induced by GILZ is LILRB4 (coding for ILT3), a protein which renders monocytes and DCs tolerogenic and has clinical relevance (16) . Human heart transplant recipients with stable grafts have circulating T suppressor cells that up-regulate ILT3 in donor antigenpresenting cells (16) . These findings demonstrate an important immunoregulatory function of ILT3. We found a significant increase of ILT3 expression in MMC-DCs. Other functionally relevant genes whose expression was modulated by MMC were MAFB (which directs differentiation away from DCs toward monocytes) (17) , CSF2RA (which transduces GM-CSF signals) (18) , MAP4K4 (which mediates TNF-␣ signaling and cell migration) (19, 20) , and GAB2 (which transmits signals delivered by cytokine-, growth factor-, and antigen-receptors) (21) . All of these genes might play a role in immunosuppression induced by MMC-treated DCs.
Taken together, the observations of Obeid et al. (33) and our team suggest that induction of apoptosis with concomitant upregulation of activatory molecules renders cells immunogenic, whereas apoptosis and up-regulation of inhibitory molecules renders cells immunosuppressive.
With respect to the possibility of developing therapeutic applications, some critical points of the present model should be discussed. One point is the use of MBP, a potential autoantigen in MS, with the aim of controlling a polyspecific immune response. It is thought that some autoimmune diseases start with an immune reaction to a single epitope expressed on an organ-specific antigen and extend to neighboring epitopes on the same or nearby molecules (4). This process, termed ''epitope spreading,'' eventually draws in a polyspecific immune response with unspecific inflammatory processes. Controlling a polyspecific response is a challenge for all antigen-specific therapies. In the 1970s, a random copolymer of amino acids, termed ''glatiramer acetate,'' was developed to mimic the composition of MBP. In clinical trials, glatiramer slowed progression of disability and significantly reduced the relapse rate of MS (36) . Studies showed that the copolymer tolerized against a variety of different myelin antigens. More recently, altered peptide ligands of MBP and other autoantigens constructed by substituting amino acids at the contact sites of these epitopes with the T cell receptor, showed similar effects in animal models (4) . These and other observations (37) indicate that the use of a single epitope can inhibit a disease caused by reactivity to multiple self-epitopes by directing unspecific regulatory mechanisms toward a certain organ. Apparently, in contrast to epitope spreading, epitope containment is also possible. Based on these observations, it is conceivable that MMC-DCs loaded with MBP, although addressing the immune response to one antigen, can also control reactions to neighboring molecules. An elegant variant of our model would be to load the inhibitory DCs with glatiramer acetate or other altered peptides derived from autoantigens. The suppressive action of peptides would be expected to be amplified.
A critical issue is the use of DCs as a clinical immunosuppressive tool. DCs are strongly stimulatory cells, and even if rendered suppressive might convert into stimulatory cells and exacerbate an autoimmune disease. Importantly, in contrast to cytokines or other biomolecules, MMC, the substance used in this study, causes irreversible changes by induction of apoptosis. This makes it unlikely that MMC-DCs regain their stimulatory function. An alternative approach for minimizing the risk of stimulation would be the use of the patient's own blood DCs. It was speculated that DCs of patients with autoimmune diseases already carry the pathogenic autoantigens (7). These natural DCs could be isolated, rendered suppressive by treatment with MMC, and reinjected into the patient.
Our in vivo data are derived from studies in the murine EAE model. It has been questioned to which extent this model reflects the pathogenesis of MS in humans (1) . Of course, no mouse data, including those derived from EAE studies, can be automatically extrapolated to humans. It is worth mentioning, however, that despite all criticism, three therapeutic compounds approved for use in MS-glatiramer acetate, mitoxantrone, and natlizumab-emerged directly from findings in the EAE model (38) . Our observations in mice gain additional relevance by the finding that T cells of MS patients are also suppressed by MBP-loaded MMC-DCs.
Despite comprehensive gene scan detection of molecular candidates, the mechanism of suppression induced by MMC-DCs has not been fully clarified. Nevertheless, our study describes a simple method for generating suppressive DCs with a clinically approved drug at nontoxic concentrations. In contrast to many other approaches, the resulting inhibitory DCs are underway to apoptosis, an irreversible process that prevents a return to stimulatory activity. Importantly, MMC-DCs have the capacity of inactivating autoreactive T cells in vitro and in vivo across species. When speaking about T cell-mediated autoimmune encephalitis, there are three decisive phases that can be approached by immunotherapy: prevention of disease, blocking of induction, and inhibition of an ongoing disease. In this article we present a method for prophylactic vaccination against EAE and for control of disease induction. These results ought to be completed by experiments trying to inhibit an ongoing disease. We are aware that the present study does not solve all problems related to EAE, but it presents an exciting an easy to perform way to prophylactic vaccination, paving the way for targeted immunosuppressive therapy in autoimmune diseases.
Materials and Methods
Mice. B10.PL mice were obtained from Jackson Laboratories. T cell receptor (TCR)-transgenic Tg4 mice (I-A u background) express a TCR derived from an encephalitogenic CD4 ϩ T cell clone specific for a MBP peptide (amino acid 1-9) (9).
Generation of DCs. Murine DCs were generated from bone marrow cells of B10.PL mice according to the protocol of Lutz et al. (10) . The cells were cultured for 9 days in GM-CSF containing medium (RPMI supplemented with 10% FCS, 2mM Lglutamine, 100 units/ml penicillin/streptomycin, 0.1 mM 2-mercaptoethanol and 10% of GM-CSF containing supernatant). For activation, 0.5 M CpG-ODN 1668 was added, and 90 min later nonadherent BMDCs were obtained. MMC (50 g/ml) was added for the last 30 min of culture, and the cells (10 6 /ml) were extensively washed. N-terminal acetylated MBP 1-10 peptide Ac-ASQKRPSQRS (Ac1-10) was synthesized in house using standard Fmoc chemistry and HPLC purified. The MBP peptide was added at a concentration of 5 M in combination with CpG-ODN. Maturation was defined by CD40 2ϩ , CD80 ϩ , CD86 ϩ , and MHCII ϩ (the last 3 markers fluctuating in their expression). The percentage of mature DCs was Ͼ80%.
Human DCs were generated according to a standard protocol as previously described (11) . Peripheral blood monocytes were cultured in the presence of 1000 units/ml rh IL-4 (Promocell, Heidelberg, Germany) and 666 units/ml rh GM-CSF (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) in RPMI medium 1640 supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, and penicillin (100 units/ml)/streptomycin (100 g/ml). On day 6 of culture, nonadherent cells (immature DCs) were collected and matured for 36 h with a combination of 500 ng/ml CD40 Ligand (CD40L) (Alexis Biochemicals) and 5 g/ml lipopolysaccharide (LPS) (Sigma-Aldrich). For myelin basic protein (MBP)-specific T cell studies, 30 g/ml MBP (Sigma-Aldrich) was added to immature DCs from MS patients or HLA-DRB1*0301 ϩ healthy blood donors until complete maturation of DCs. Maturation was defined by the following phenotype: CD14 Ϫ , HLA-DR 2ϩ , CD80 2ϩ , CD86 2ϩ , and CD83 ϩ . The percentage of mature DCs was Ͼ80%. For certain studies, MMC (10 -100 g/ml) was added to the culture medium of mature DCs; after 30 min of incubation at 37°C, the cells were extensively washed.
T Cell Studies in Vitro.
Murine lymphocytes were cultured with bone marrowderived DCs. Human peripheral blood lymphocytes of MS patients were coincubated with autologous MBP-loaded DCs. In a parallel experiment, DRB1*0301-DCs from healthy donors were loaded with MBP and coincubated with MBP-specific CD4 ϩ T cells (clone ES-BP8T) as previously described (11) . In a control experiment, the DCs were loaded with an irrelevant peptide with comparable interaction with DRB1*0301. The HLA restriction was calculated by the SYFPEITHI software. Cocultures were performed at a DC:T cell ratio of Յ 1:10. T cell proliferation was measured by [ 3 H]thymidine incorporation. EAE Model. EAE was induced by i.v. injection of 5 ϫ 10 6 activated DCs (in 0.2 ml) pulsed with 5 M autoantigenic MBP peptide (ϩ/Ϫ MMC). On day 1 and 2 after immunization, each mouse was injected intraperitonially with 200-ng pertussis toxin (Calbiochem) in 500-l Dulbecco's PBS. Symptoms were evaluated daily according to the Coligan score.
Affymetrix Microarray. Total RNA was extracted from DCs 18 hr after MMC treatment by the isothiocyanate method (RNeasy RNA isolation kit; Qiagen, Hilden, Germany) according to the manufacturer's instructions. DNase treatment was carried out by using DNase I (Applied Biosystems, Darmstadt, Germany). Total RNA (5 g) was converted into ds-cDNA using T7-(dT)24 primers and the Superscript Choice system (Invitrogen, Karlsruhe, Germany). Biotin-labeled cRNA was generated from the cDNA sample by in vitro transcription using the BioArray HighYield RNA Transcript Labeling kit (Enzo Diagnostics, New York, NY). The purified and fragmented biotin-labeled cRNA was then hybridized to U133 Plus 2.0 gene chips (Affymetrix, High Wycombe, UK). The hybridized gene chips were stained with streptavidin-phycoerythrin (MoBiTec, Gö ttingen, Germany) and scanned using the GeneArray scanner (Affymetrix). RNA quality was confirmed by spectrophotometric examination and by assessing 5Ј/3Ј ratios of control genes provided on the test 3 array. Microarray data of samples derived from 3 unrelated DC donors were analyzed. Untreated or MMC-treated DCs of the same healthy donor were used. Data analysis was performed according to instructions provided by Affymetrix using the Affymetrix Data Mining tool (DMT 4.0), the Affymetrix publishing tool (MDB 3.0), and the statistical data analysis software (Affymetrix Microarray Suite 5.0). Comparisons between human mitomycin C-treated and untreated DCs were done for genes with a positive detection call in at least one experimental group and with a fold change of at least 1.2 (corresponding to a signal log ratio between the two experimental groups of less than Ϫ0.3 or more than 0.3). Functional classifications from Gene Ontology (GO) Consortium (www.geneontology.org) were assigned to each identified gene.
FACS Analysis.
Human DCs were stained with fluorescein isothiocyanate (FITC)-labeled annexin V and 7-amino-actinomycin (7-AAD) to confirm apoptotic cell death.
DC staining was performed with fluorescence (FITC, PE)-labeled monoclonal antibodies (to MHC II, CD80, CD86,) to concentrations indicated by the manufacturers (BD Biosciences).
Approval for Animal and Human Studies. Animal experiments were approved by the Animal Welfare Board of the Governmental Office Karlsruhe. Studies of human sera and cells were approved by the University of Heidelberg Ethics Committee.
Statistics.
Results are shown as mean Ϯ SD or SEM as indicated. Single values of T cell proliferation represent the mean [ 3 H]thymidine incorporation (cpm) of triplicate cultures and are given in percentage of the positive control (ϭ 100% proliferation) or counts per minute. P values were calculated by the unpaired Student's t test using SigmaStat software (SPSS). Statistical significance was set at P Ͻ 0.05.
